Literature DB >> 29753585

High-sensitivity C-reactive protein, low-grade systemic inflammation and type 2 diabetes mellitus: A two-sample Mendelian randomization study.

R Noordam1, C H Oudt2, M M Bos2, R A J Smit3, D van Heemst2.   

Abstract

BACKGROUND AND AIMS: The role of inflammation in type 2 diabetes mellitus (T2D) remains unclear. We investigated the associations of high sensitivity C-reactive protein (hsCRP) concentration with T2D and glycemic traits using two-sample Mendelian Randomization. METHODS AND
RESULTS: We used publically available summary-statistics data from genome-wide association studies on T2D (DIAGRAM: 12 171 cases; 56 862 controls) and glycemic traits (MAGIC: 46 186 participants without diabetes mellitus). We combined the effects of the genetic instrumental variables through inverse-variance weighting (IVW), and MR-Egger regression and weighted-median estimation as sensitivity analyses which take into account potential violations (e.g., directional pleiotropy) of the assumptions of instrumental variable analyses. Analyses were conducted using 15 known hsCRP genetic instruments among which 6 instruments are hsCRP specific and not involved in inflammatory processes beyond hsCRP concentration regulation. Though we found no association between the combined effect of the genetic instrumental variables for hsCRP and T2D with IVW (odds ratio per 1 ln [hsCRP in mg/L]: 1.15; 95% confidence interval: 0.93, 1.42), we found associations for T2D with MR-Egger regression and weighted-median estimation (odds ratio with 95% confidence interval per 1 ln [hsCRP in mg/L], MR-Egger regression: 1.29; 1.08, 1.49; weighted-median estimator: 1.21; 1.02, 1.39). We found no association with T2D for the combination of hsCRP-specific genetic instruments nor did we found associations with glycemic traits in any of the analyses.
CONCLUSION: Evidence was provided for a potential causal association between hsCRP and T2D, but only after considering directional pleiotropy. However, hsCRP was not causally associated with glycemic traits.
Copyright © 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Inflammation; Mendelian randomization; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 29753585     DOI: 10.1016/j.numecd.2018.03.008

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  5 in total

1.  Temporal relationship between inflammation and insulin resistance and their joint effect on hyperglycemia: the Bogalusa Heart Study.

Authors:  Yinkun Yan; Shengxu Li; Yang Liu; Lydia Bazzano; Jiang He; Jie Mi; Wei Chen
Journal:  Cardiovasc Diabetol       Date:  2019-08-23       Impact factor: 9.951

Review 2.  Potential Role of Natural Plant Medicine Cyclocarya paliurus in the Treatment of Type 2 Diabetes Mellitus.

Authors:  Han Wang; Cheng Tang; Zezheng Gao; Yishan Huang; Boxun Zhang; Jiahua Wei; Linhua Zhao; Xiaolin Tong
Journal:  J Diabetes Res       Date:  2021-12-27       Impact factor: 4.011

Review 3.  A Meta-Analysis of the Effects of Different Exercise Modes on Inflammatory Response in the Elderly.

Authors:  Haotian Zhao; Zhijian He; Hezhang Yun; Ruifu Wang; Chang Liu
Journal:  Int J Environ Res Public Health       Date:  2022-08-22       Impact factor: 4.614

4.  An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study.

Authors:  Shuai Yuan; Susanna C Larsson
Journal:  Diabetologia       Date:  2020-09-08       Impact factor: 10.122

Review 5.  Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies.

Authors:  Georgios Markozannes; Charalampia Koutsioumpa; Sofia Cividini; Grace Monori; Konstantinos K Tsilidis; Nikolaos Kretsavos; Evropi Theodoratou; Dipender Gill; John Pa Ioannidis; Ioanna Tzoulaki
Journal:  Eur J Epidemiol       Date:  2020-09-25       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.